Release of monocyte migration signals by breast cancer cell lines after ablative and fractionated γ-irradiation by Roman Hennel et al.
Release of monocyte migration signals by breast
cancer cell lines after ablative and fractionated
γ-irradiation
Hennel et al.
Hennel et al. Radiation Oncology 2014, 9:85
http://www.ro-journal.com/content/9/1/85
Hennel et al. Radiation Oncology 2014, 9:85
http://www.ro-journal.com/content/9/1/85RESEARCH Open AccessRelease of monocyte migration signals by breast
cancer cell lines after ablative and fractionated
γ-irradiation
Roman Hennel, Nikko Brix, Karin Seidl, Anne Ernst, Heike Scheithauer, Claus Belka and Kirsten Lauber*Abstract
Background: Radiotherapy, administered in fractionated as well as ablative settings, is an essential treatment
component for breast cancer. Besides the direct tumor cell death inducing effects, there is growing evidence that
immune mechanisms contribute - at least in part - to its therapeutic success. The present study was designed to
characterize the type and the extent of cell death induced by fractionated and ablative radiotherapy as well as its
impact on the release of monocyte migration stimulating factors by dying breast cancer cells.
Methods: Cell death and senescence assays were employed to characterize the response of a panel of breast
cancer cell lines with different receptor and p53 status towards γ-irradiation applied in a fractionated (daily doses of
2 Gy) or ablative setting (single dose of 20 Gy). Cell-free culture supernatants were examined for their monocyte
migration stimulating potential in transwell migration and 2D chemotaxis/chemokinesis assays. Irradiation-induced
transcriptional responses were analyzed by qRT-PCR, and CD39 surface expression was measured by flow cytometry.
Results: Fast proliferating, hormone receptor negative breast cancer cell lines with defective p53 predominantly
underwent primary necrosis in response to γ-irradiation when applied at a single, ablative dose of 20 Gy, whereas
hormone receptor positive, p53 wildtype cells revealed a combination of apoptosis, primary, and secondary
(post-apoptotic) necrosis. During necrosis the dying tumor cells released apyrase-sensitive nucleotides, which
effectively stimulated monocyte migration and chemokinesis. In hormone receptor positive cells with functional
p53 this was hampered by irradiation-induced surface expression of the ectonucleotidase CD39.
Conclusions: Our study shows that ablative radiotherapy potently induces necrosis in fast proliferating, hormone
receptor negative breast cancer cell lines with mutant p53, which in turn release monocyte migration and
chemokinesis stimulating nucleotides. Future studies have to elucidate, whether these mechanisms might be
utilized in order to stimulate intra-tumoral monocyte recruitment and subsequent priming of adaptive anti-tumor
immune responses, and which breast cancer subtypes might be best suited for such approaches.
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Radiotherapy is a crucial treatment part for the manage-
ment of breast cancer. Commonly, it is applied in daily
fractions of 1.8-2 Gy for 5 to 7 weeks to a total dose of 50
to 66 Gy [1-5]. Fractionated irradiation schemes are con-
sidered to be beneficial for the reduction of tumor burden,
since they are intended to exploit the discrepant DNA re-
pair capacity of tumor and normal tissue. Larger, irrepar-
able damage per unit dose is induced in the tumor,
whereas efficient DNA repair mechanisms compensate for
the damage induced by the daily irradiation fractions in
the adjacent normal tissue. Moreover, tumor reoxygena-
tion can occur between the fractions and tumor cells can
redistribute to more radiosensitive phases of the cell cycle
[6]. At present several clinical trials support the use of
higher doses per fraction in order to shorten the overall
treatment period. In the UK doses of 2.66 Gy per fraction
are already accepted practice [7,8], and ongoing trials will
determine in how far even higher single doses (5.7-6 Gy)
may define a new optimum. Additionally, there are spe-
cific applications, where ablative, large single doses of
10–25 Gy are delivered locally to the tumor, for instance
during intra-operative radiotherapy (IORT) [9-11].
The tumor cell death inducing effect of radiotherapy has
been regarded as the major determinant of its therapeutic
success for a long time. Nevertheless, there is accumulat-
ing experimental evidence that innate as well as adaptive
immune responses contribute - at least in part - to the re-
duction of tumor burden and tumor control [12]. Essen-
tially, previous studies have revealed that radiotherapy
stimulates a type I interferon-dependent priming of adap-
tive anti-tumor immune responses, including tumor-
specific CD8+ cytotoxic T cells, by antigen-presenting cells
(APCs) [13-17]. These effects were only observed in case
of ablative but not fractionated radiotherapy, and the
underlying mechanisms remain largely elusive. Conceiv-
ably, tumor cells respond differently to γ-irradiation when
applied in an ablative or a fractionated setting. The mode
as well as the extent of cell death might vary substantially.
And since different types of cell death are well known to
have different immunological consequences, we proposed
that the extent as well as the type of tumor cell death in
response to radiotherapy might govern and shape the sub-
sequent anti-tumor immune responses [18]. For systemic
anthracycline therapy it has been reported that danger sig-
nals released from dying tumor cells trigger the activation
of APCs and subsequent T cell priming [19]. One of the
initial steps in this scenario was the intra-tumoral recruit-
ment of monocytic precursor cells, which then differenti-
ated into highly potent APCs [20]. Therefore, the present
study was designed to analyze the cell death response of
different breast cancer cell lines towards fractionated and
ablative radiotherapy and its impact on the release of sig-
naling molecules, which stimulate monocyte migration.We observed that fast proliferating, hormone receptor
negative, and p53 mutant cell lines predominantly under-
went necrosis in response to radiotherapy, particularly
when administered in an ablative regime. Necrosis induc-
tion was paralleled by the release of apyrase-sensitive nu-
cleotides, which effectively stimulated monocyte migration
and chemokinesis. In hormone receptor positive breast
cancer cells with functional p53 this process was impaired
by irradiation-induced surface expression of the ectonu-
cleotidase CD39 that degrades extracellular nucleotides.
Hence, our study opens the question, whether ablative
radiotherapy might be utilized for targeted necrosis induc-
tion in fast proliferating, hormone receptor negative breast
cancer with defective p53 in order to stimulate intra-
tumoral monocyte recruitment and subsequent priming of
adaptive anti-tumor immune responses.
Methods
Cells and reagents
The human breast cancer cell lines MCF7, BT474,
HCC1937, HCC1806, MDA-MB468, and BT549 were
obtained from ATCC (Manassas, VA, USA) or CLS
(Heidelberg, Germany), and were cultured in RPMI-
1640 medium supplemented with 10% heat-inactivated
fetal calf serum (FCS), 100 units/ml penicillin, 0.1 mg/ml
streptomycin, and 10 mM HEPES (all from Life Technolo-
gies, Karlsruhe, Germany) at 37°C and 5% CO2 (MCF7,
BT474, HCC1937, and HCC1806), or in DMEM (BT549),
or DMEM/F12 (1:1) medium (MDA-MB468) supple-
mented with 10% heat-inactivated FCS, 100 units/ml peni-
cillin, and 0.1 mg/ml streptomycin at 37°C and 7.5% CO2,
respectively.
THP-1 cells were obtained from ATCC and were cul-
tured in RPMI-1640 medium supplemented with 10%
heat-inactivated FCS, 100 units/ml penicillin, 0.1 mg/ml
streptomycin, and 10 mM HEPES. Preparation of human
peripheral blood monocytes was carried out as described
previously [21]. Briefly, PBMCs were prepared from hepa-
rinized blood of healthy volunteers by Biocoll density gra-
dient centrifugation (Biochrom AG, Berlin, Germany).
Monocytes were positively selected from PBMCs with
anti-CD14 magnetic beads (Miltenyi, Bergisch Gladbach,
Germany) according to the manufacturer’s recommenda-
tions and allowed to recover for 1 day in X-Vivo 15
medium (Lonza, Basel, Switzerland) supplemented with
10% autologous serum, 100 units/ml penicillin, and
0.1 mg/ml streptomycin before further use.
The p53 status of all breast cancer cell lines was deter-
mined by cDNA sequencing. Full length PCR products
were generated from cDNA (80 ng per reaction) by
employing 5 units HotStar HiFidelity DNA-Polymerase
in 1 × HotStar HiFidelity reaction buffer, and 1 × Q so-
lution (all from Qiagen, Hilden, Germany) in the pres-
ence of 1 μM of each primer (p53 Forward 5′-ATG
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GTC TGA GTC AGG CCC TTC T-3′, synthesized by
Sigma-Aldrich, Taufkirchen Germany) in 100 μl final
volume (cycling program: 1 × 5′ 95°C; 40 × 15″ 95°C, 1′
60°C, 1′30″ 72°C; 1 × 10′ 72°C). The amplicons were
purified by the NucleoSpin Extract II Kit (Macherey &
Nagel, Dueren, Germany), and sequencing was per-
formed by Seqlab Sequencing Services (Goettingen,
Germany).
Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluor-
omethylketone (zVAD-fmk) was obtained from Bachem
(Bubendorf, Switzerland), necrostatin-1 from Enzo Life
Sciences (Loerrach, Germany), calcein-AM from Merck
Calbiochem (Darmstadt, Germany), bafilomycin A1
and ARL-67156 from Tocris R&D Systems (Wiesbaden,
Germany). The annexin V-FITC apoptosis detection
kit, anti-CD39-PE, anti-CD73-FITC, and anti-CD203c-
APC antibodies were purchased from BD Biosciences
(Heidelberg, Germany), and 5-dodecanoylaminofluorescein-
di-β-galactopyranoside (C12-FDG-FITC) was from Life
Technologies.
Mouse monoclonal westernblot antibodies anti-p21WAF1
and anti-vinculin were obtained from BD Biosciences or
Sigma-Aldrich, respectively. The chemokines SDF-1α and
WKYMVm (agonist of formyl-peptide receptors 1, 2, and
3) were from R&D Systems, adenosine 5′-triphosphate
disodium salt (ATP) from Sigma-Aldrich, and nucleotide
diphosphohydrolase (apyrase) was purchased from New
England Biolabs (Frankfurt, Germany).
Growth analyses and determination of doubling times
Cells were seeded into 24-well plates (2.5 × 104 cells per
well) and allowed to adhere for 5 h. Medium was replaced
(medium supplemented with 10% or 2.5% FCS was used
as indicated), and cells were grown for up to 4 days. Every
day, cells were harvested by trypsinization and cell num-
bers were determined by counting. Growth curves were
generated by plotting log cell number (y-axis) versus time
(x-axis), and doubling times were calculated on the basis
of the slopes of the corresponding regression lines.
X-ray treatment and production of cell-free culture
supernatants
Cells were seeded into 6-well (0.5-1 × 106 cells per well)
or 24-well plates (0.25-1 × 105 cells per well) in culture
medium supplemented with 10% FCS and allowed to ad-
here overnight. Immediately prior to irradiation, culture
medium was replaced by serum-reduced medium (2.5%
FCS). Cells were irradiated at the indicated doses with a
Mueller RT-250 γ-ray tube (200 kV and 10 mA, Thoraeus
filter, 1 Gy in 1 min 52 s). Fractionated irradiation was car-
ried out daily. Cell-free supernatants were collected by
centrifugation (10,000 g, 5 min, 4°C) at the indicated time
points and stored at −80°C until further use.SDS-PAGE and Westernblot analyses
Reducing 6-15% gradient SDS-PAGE and Westernblot
analyses of whole cell lysates were performed as described
previously [22,23] with 300 μg protein extract per lane.
After electrophoretic separation, proteins were transferred
to PVDF Immobilon FL membranes (Merck Millipore,
Darmstadt, Germany). Membranes were blocked with 5%
low-fat milk in TBST buffer (13 mM Tris–HCl pH 7.5,
150 mM NaCl, and 0.02% Triton X-100) and incubated
with monoclonal mouse antibodies against p21WAF1 (BD
Biosciences) or vinculin (Sigma-Aldrich), respectively. After
incubation with the corresponding IRDye-conjugated sec-
ondary antibodies (LI-COR Biosciences, Bad Homburg,
Germany) and extensive washing in TBST buffer, IRDye
fluorescence was read with a LI-COR Odyssey scanner.
Flow cytometric measurement of phosphatidylserine
externalization, plasma membrane integrity, senescence-
associated β-galactosidase activity, and ectonucleotidase
surface expression
All FACS measurements were performed on an LSRII
cytometer (BD Biosciences) and data were analyzed with
FACSDiva (BD Biosciences) or FlowJo 7.6.3 Software
(Tree Star Inc., Ashland, OR, USA), respectively.
Externalization of phosphatidylserine (PS) and plasma
membrane integrity were measured by staining with
annexin V-FITC/propidium iodide (annexin V staining
kit, BD Biosciences) as described previously [24]. Briefly,
1 × 105 cells were incubated with 5 μl FITC-labeled
annexin V in 50 μl staining buffer (both from BD Biosci-
ences) supplemented with 5 μg/ml propidium iodide
(PI, Sigma-Aldrich) for 30 min on ice. Following an add-
itional washing step in staining buffer, annexin V-FITC
and PI fluorescence were assessed by flow cytometry.
Cells with positive annexin V-FITC but negative PI sig-
nal were considered apoptotic, and cells double-positive
for annexin V-FITC and PI staining were considered
necrotic. In order to distinguish primary from secondary
necrotic cells, the poly-caspase inhibitor carbobenzoxy-
valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone
(zVAD-fmk, Bachem) was employed. zVAD-fmk blocks
apoptosis and the transition into secondary necrosis.
Hence, annexin V-FITC/PI double positive cells, which
were detected in the presence of zVAD-fmk, were con-
sidered primary necrotic.
Senescent cells were stained by using 5-dodecanoylamino-
fluorescein-di-β-galactopyranoside (C12-FDG-FITC, Life
Technologies), a fluorogenic substrate of senescence-
associated β-galactosidase [25]. At the indicated time
points after irradiation, cells were incubated with 100 nM
bafilomycin A1 (Tocris R&D Systems) in serum-free
medium for 1 h at 37°C for lysosomal alkalinization. Sub-
sequently, C12-FDG-FITC was added at a final concentra-
tion of 50 μM, and cells were incubated for 1 h at 37°C to
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PBS, cells were collected by trypsinization and analyzed by
flow cytometry. Cells with high C12-FDG-FITC and high
SSC signal were considered senescent.
For ectonucleotidase surface staining, 1 × 105 cells
were incubated with 2 μl anti-CD39-PE, anti-CD73-
FITC, or anti-CD203c-APC in 50 μl FACS staining buf-
fer (all from BD Biosciences) for 30 min on ice. After
two washing steps in FACS staining buffer, cells were an-
alyzed by flow cytometry. Relative surface expression
was calculated as the median fluorescence intensities of
anti-ectonucleotidase staining subtracted by the corre-
sponding isotype controls.
Transwell migration assay
Transmigration assays were performed in 96-well
Multiscreen-MIC transwell chambers with 5 μm pore size
(Merck Millipore) as described before [22,23]. In brief,
1 × 105 calcein-labeled THP-1 cells per well were seeded
in a final volume of 80 μl onto the 96-well filter Plate.
320 μl of supernatants or chemokines dissolved in serum-
free RPMI-1640 medium were added to the lower cham-
ber. The filter was mounted onto the lower chamber and
transmigration was allowed for 90 min at 37°C. Subse-
quently, the cells in the lower chamber were collected by
centrifugation and lysed in 100 μl lysis buffer (20 mM
HEPES-K pH 7.4, 84 mM KCl, 10 mM MgCl2, 0.2 mM
EDTA, 0.2 mM EGTA, 0.5% Igepal). Green calcein fluor-
escence was quantified with a Synergy MX fluorescence
reader (BioTek Instrumtents GmbH, Bad Friedrichshall,
Germany), and transmigration was calculated as percent-
age of total cells deployed.
In some experiments, supernatants were subjected to
ultrafiltration with VivaSpin 2 centrifuge tubes with an
exclusion limit of 10 kDa (Sartorius Stedim Biotech,
Goettingen, Germany) as described before [22]. After
passing the entire liquid phase through the filter, the fil-
ter was rinsed well with culture medium and the volume
of the two fractions (substances smaller and larger than
10 kDa) was readjusted to the initial volume employed.
Then, the fractions were applied to a transmigration
assay.
Apyrase treatment was carried out by adding 500
milliunits of nucleotide diphosphohydrolase (apyrase,
New England Biolabs) to 1.5 ml culture supernatant and
allowing nucleotide degradation for 30–50 min at 37°C.
Heat-inactivated apyrase served as a control. After diges-
tion, supernatants were used in transwell migration or
chemotaxis/chemokinesis assays, respectively.
Chemotaxis/chemokinesis assay in IBIDI μ-slide 2D
chemotaxis chambers
IBIDI μ-slide 2D chemotaxis chambers (IBIDI, Munich,
Germany) were used to analyze chemotaxis and/orchemokinesis of primary human monocytes by live cell
tracking as described before [22]. Briefly, monocytes were
seeded into the observation area of the chamber in X-Vivo
15 medium supplemented with 5% autologous serum.
Adherence was allowed for 15 min, and non-adherent
cells were carefully washed away. The reservoirs of the
chamber were filled with medium supplemented with
5% autologous serum, and the stimulus was added to
the upper reservoir. The slide was mounted onto the
heated stage of an AxioObserver Z1 inverted microscope
(Zeiss, Goettingen, Germany), and time-lapse video mi-
croscopy was performed at 37°C and 5% CO2 for 3 h at
5 × magnification. Pictures were taken every 2 min and
migration of 40 randomly picked cells was tracked with
the ImageJ manual tracking plug-in. Accumulated distance,
euclidean distance (linear distance between start and end
position), and y forward migration index (yFMI =mean of
(endpoint in y direction/accumulated distance) of all cells
analyzed) were determined with the IBIDI chemotaxis and
migration tool (IBIDI). Analysis window was set from
10 min to 2 h and 10 min (2 h time frame). Apyrase treat-
ment of culture supernatants was performed as described
for transwell migration assays.
Quantitative Realtime RT-PCR
RNA isolation and qRT-PCR analyses were performed
as described previously [26,27]. Briefly, total RNA was
extracted with the NucleoSpin RNA II Kit (Macherey &
Nagel). 1 μg of isolated RNA was subjected to reverse
transcription with 200 units RevertAid reverse transcript-
ase in the presence of 50 μM random hexamers, 5 μM
Oligo(dT)18, 400 μM dNTPs, and 1.6 units/μl Ribolock
RNase inhibitor (all from Fermentas, St. Leon-Rot,
Germany). The resulting cDNA (20 ng per reaction)
was applied to qRT-PCR analyses (20 μl final volume) with
300 nM primers (synthesized by Sigma-Aldrich) in 1×
Maxima SYBR Green qPCR Mastermix (Fermentas) and a
standard cycling protocol (10 min 95°C, 45× (15 s 95°C,
30 s 60°C)) on an LC480 qPCR cycler (Roche Applied
Science, Penzberg, Germany). The following primer pairs
were used: p21WAF1 Forward 5′-CTG GAG ACT CTC
AGG GTC GAA A-3′, p21WAF1 Reverse 5′-AGT GGT
AGA AAT CTG TCA TGC TGG T-3′, Egr-1 Forward 5′-
GAG CAC CTG ACC GCA GAG TC-3′, Egr-1 Reverse
5′-CCA GCA CCT TCT CGT TGT TCA-3′, 18S rRNA
Forward 5′-CGG CTA CCA CAT CCA AGG AA-3′, 18S
rRNA Reverse 5′-GCT GGA ATT ACC GCG GCT-3′,
β2-microglobulin Forward 5′-TGC TCG CGC TAC TCT
CTC TTT C-3′, β2-microglobulin Reverse 5′-TCT CTG
CTG GAT GAC GTG AGT AAA C-3′. Relative quantifi-
cation was performed by employing the standard curve
method, and the results were normalized on the means of
18S rRNA and β2-microglobulin. Untreated control cells
were used as calibrator.
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A few previous studies have shown that radiotherapy
can stimulate anti-tumor immune reactions, which
contribute to the reduction of tumor burden [13-17]. In
principle, the authors observed a type I interferon-
dependent, APC-mediated priming of tumor-specific
CD8+ T cell responses. Notably, the induction of these
T cell responses was limited to ablative radiotherapy re-
gimes, where γ-irradiation was applied at high single
doses of more than 10 Gy. The tumor cell response to-
wards low or high single doses as well as fractionated
γ-irradiation in terms of apoptosis, necrosis, and senes-
cence induction is likely to diverge substantially, and
different types of tumor cell death are well known
to stimulate different types of immunological conse-
quences. Therefore, we hypothesized that the type of
tumor cell response, which is induced by different re-
gimes of radiotherapy, might shape the immunologicalFigure 1 Breast cancer cell lines of different origin reveal different do
in the present study. Molecular subtype, tumor type and receptor status ha
determined by cDNA sequencing. (B) Growth curves of breast cancer cell l
Means ± s.d. of triplicates are shown. (C) Doubling times of exponentially g
(D) p21WAF1 induction as an indicator of p53 functionality was examined in
points by 6-15% SDS-PAGE (300 μg protein extract per lane) and subsequeconsequences [18,28]. In order to address this issue, we
analyzed the tumor cell response towards different re-
gimes of γ-irradiation in three breast cancer lines:
HCC1937, MCF7, and BT474. We deliberately chose
cell lines of divergent molecular breast cancer subtypes
as well as divergent estrogen, progesterone, and Her2/
neu receptor status (Figure 1A) [29,30]. The cell lines
exhibited clear differences in proliferation rates with
short (MCF7, 24 h), intermediate (HCC1937, 46 h), and
long (BT474, 77 h) doubling times in the presence of
2.5% FCS (Figure 1B, C). p53 mutation status and func-
tion were confirmed by cDNA sequencing and by im-
munoblot analysis of p21WAF1 induction in response to
γ-irradiation at 4 Gy. Only MCF7 cells, which have
been reported to possess wildtype p53 [30], revealed
irradiation-induced upregulation of p21WAF1 protein
expression starting approximately 4 h and reaching a
plateau around 8 h after irradiation.ubling times and p53 functionality. (A) Breast cancer cell lines used
ve previously been reported [29], and p53 mutational status was
ines were generated in the presence of 2.5% or 10% FCS, respectively.
rowing cells were calculated from the data shown in (B).
whole cell lysates after irradiation with 4 Gy at the indicated time
nt immunoblot analysis. Vinculin served as a loading control.
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of cell death and senescence in breast cancer cell lines
Next, we investigated the type of tumor cell response to-
wards different regimes of γ-irradiation. Cells were irradi-
ated at single doses of 2 Gy or 20 Gy, or daily fractions of
2 Gy, respectively, and the percentage of apoptotic, nec-
rotic, and senescent cells was measured by flow cytometry
over a period of 4 days after irradiation (Figure 2A, D). In
order to distinguish between primary and secondary
(post-apoptotic) necrosis, we employed the poly-caspase
inhibitor zVAD-fmk, which blocks apoptosis and the sub-
sequent transit into secondary necrosis (Figure 2B). The
necroptosis inhibitor necrostatin-1 was used to assess the
contribution of necroptosis in our experimental system
(Figure 2C). We made the following observations: (i) TheFigure 2 Different γ-irradiation regimes induce different modalities of c
apoptosis, necrosis, and senescence. Breast cancer cell lines were left untreate
respectively. Induction of apoptosis and necrosis was determined 1–4 days af
V-FITC positive, PI negative cells were considered apoptotic, double positive c
flow cytometric SA-β-gal staining with the fluorogenic substrate C12-FDG-FITC
senescent. Means ± s.d. of triplicates are depicted. (B) Induction of apoptosis a
membrane integrity were measured as in (A) in the presence of 50 μM of the
(C) Induction of apoptosis and necrosis in the presence of necrostatin-1. PS e
(A) in the presence of 50 μM of the necroptosis inhibitor necrostatin-1. Means
cells stained for SA-β-gal activity with the fluorogenic substrate C12-FDG-FITCstrongest response of apoptosis, necrosis, and senescence
induction was detected in fast proliferating MCF7 and
HCC1937 cells. Slowly proliferating BT474 cells revealed
only a moderate degree of apoptosis, necrosis, or senes-
cence induction, respectively. (ii) Fast proliferating, p53
wildtype MCF7 cells underwent a combination of apop-
tosis and necrosis – primary as well as secondary (post-
apoptotic) necrosis. Appearance of senescent MCF7 cells
was only observed in response to ablative irradiation with
20 Gy. (iii) HCC1937 cells with mutant p53 predominantly
underwent primary, apoptosis-independent necrosis and
senescence. (iv) Of all γ-irradiation regimes applied, abla-
tive irradiation at 20 Gy provoked the most pronounced
cellular responses in terms of apoptosis, necrosis, and sen-
escence induction. These findings allow the conclusionell death and senescence in breast cancer cell lines. (A) Induction of
d or γ-irradiated at single doses of 2 Gy, 20 Gy, or daily fractions of 2 Gy,
ter irradiation by annexin V-FITC/PI staining and FACS analysis. Annexin
ells were considered necrotic. Senescence induction was measured by
. Cells with high C12-FDG-FITC and high SSC signal were considered
nd necrosis in the presence of zVAD-fmk. PS externalization and plasma
poly-caspase inhibitor zVAD-fmk. Means ± s.d. of triplicates are shown.
xternalization and plasma membrane integrity were measured as in
± s.d. of triplicates are shown. (D) Representative dot plots of HCC1937
.
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ablative setting of high single doses - primarily induces cell
death and senescence in fast proliferating cancer cells. In
cells with wildtype p53, a combination of apoptosis, pri-
mary, and secondary (post-apoptotic) necrosis is the major
consequence, whereas cells lacking functional p53 mainly
undergo primary necrosis and senescence. The contribu-
tion of necroptosis in this context is only a marginal one.
These findings are in line with reports showing that p53 is
crucial for irradiation-induced apoptosis, either via tran-
scriptional activation of pro-apoptotic p53 target genes,
including Bax, Puma, and Noxa, or via transcription-
independent pathways, respectively [31-35]. In addition,
p53 has been reported to be essential for establishing and
maintaining certain types of senescence [36,37]. Neverthe-
less, p53-independent forms of senescence apparently do
exist [38].
Ablative γ-irradiation induces the release of low molecular
weight, apyrase-sensitive factors, which stimulate
monocyte chemokinesis
In order to stimulate productive, tumor-specific immune
responses by radiotherapy, irradiated, dying tumor cells
have to be detected and engulfed by APCs, which subse-
quently migrate into the draining lymph nodes, process
and (cross-) present ingested tumor-antigens, and thus
finally prime adaptive anti-tumor immune responses, in-
cluding tumor-specific CD8+ cytotoxic T cells [18,39,40].
The initial step in this scenario is the recruitment of
APCs by dying tumor cells - either tissue resident APCs
or circulating monocytic precursors, which in turn can
give rise to dendritic cells or macrophages, respectively.
In order to examine the process of monocyte migration
in the context of different radiotherapeutic regimes, we
collected cell-free supernatants of HCC1937, MCF7, and
BT474 cells 1–4 days after γ-irradiation with single
doses of 2 Gy or 20 Gy, or daily fractions of 2 Gy, and
applied them to transwell migration assays with monocytic
THP-1 cells (Figure 3A). A clear and time-dependent
migratory response was detected with supernatants of
HCC1937 cells, which had been ablatively irradiated at a
single dose of 20 Gy. Significantly reduced, yet still well
detectable was THP-1 cell migration towards supernatants
of HCC1937 cells, which had been subjected to the frac-
tionated irradiation scheme with daily doses of 2 Gy. Of
note, the migration stimulating capacity of HCC1937 su-
pernatants paralleled necrosis induction and preceded the
onset of senescence in HCC1937 cells (Figure 2) suggest-
ing that necrotic and not senescent cells were the source
of monocyte migration signals. Along this line, it was not
surprising that supernatants of irradiated BT474 cells,
which revealed very little necrosis induction even in
response to irradiation with 20 Gy (Figure 2), did not
significantly stimulate monocyte migration (Figure 3A).However, MCF7 cells despite extensively undergoing pri-
mary and secondary necrosis in response to ablative ir-
radiation with 20 Gy as well as fractionated irradiation
with daily doses of 2 Gy (Figure 2), did also not release
detectable amounts of monocyte attraction signals
(Figure 3A). Before addressing this issue in greater de-
tail, we focused on the process of monocyte attraction
by irradiated, necrotically dying HCC1937 cells.
Different necrotic cell-derived danger signals have
been reported to be involved in monocyte recruitment.
High molecular weight compounds, like heat shock pro-
teins, high-mobility group box 1 protein (HMGB-1),
S100 protein family members, small nuclear ribonucleo-
proteins, monosodium urate crystals, or nucleic acids, as
well as low molecular weight compounds, like nucleo-
tides, have been described [41]. In order to elucidate,
which of these factors might contribute to monocyte at-
traction by ablatively irradiated HCC1937 cells, cell-free
supernatants were subjected to ultrafiltration with an ex-
clusion limit of 10 kDa. THP-1 cell migration towards
the filtered supernatants was virtually not affected after
high molecular weight compounds had been removed.
Comparable results were obtained for purified ATP
(MW= 507 Da), whereas the classical CXC chemokine
SDF-1α (MW= 11 kDa) was more or less completely
retained in the fraction with a molecular weight of more
than 10 kDa, thus confirming a proof-of-principal of this
procedure (Figure 3B left panel). Furthermore, incuba-
tion with active but not heat-inactivated nucleotide dipho-
sphohydrolase (apyrase) completely abrogated THP-1 cell
migration towards supernatants of HCC1937 cells that
had been irradiated at 20 Gy. Again, parallel results were
observed for purified ATP, whereas migration towards
SDF-1α was basically not impaired by apyrase digestion
(Figure 3B right panel). These findings allow the conclu-
sion that the THP-1 cell migration stimulating factors,
which are released by ablatively irradiated, necrotically
dying HCC1937, are of low molecular weight and sensitive
to apyrase treatment, apparently nucleotides. Different
studies have previously provided evidence for the involve-
ment of extracellular nucleotides in the recruitment of
monocytes, macrophages, and dendritic cells by dying cells
in vitro and in vivo [20,42,43]. However, currently it is be-
ing controversially discussed, whether nucleotides per se
do stimulate directional chemotactic responses in mono-
cytes and macrophages, or if they rather act as auto- and
paracrine amplifiers of other chemotactic stimuli, such as
complement C5a [44,45].
Therefore, we next characterized the migratory re-
sponse of primary human monocytes towards superna-
tants of γ-irradiated HCC1937 cells by time-lapse video
microscopy in 2D chemotaxis/chemokinesis chambers.
The obtained trajectory paths and the detailed analysis
of accumulated and euclidean distance as well as the
Figure 3 Ablative γ-irradiation induces the release of low molecular weight, apyrase-sensitive factors, which stimulate THP-1 cell
migration. (A) THP-1 cell transwell migration. Breast cancer cells were left untreated or γ-irradiated as in Figure 2. Cell-free supernatants were
collected 1–4 days after irradiation and applied to transwell migration assays with THP-1 cells. Means ± s.d. of quadruplicates are given. Asterisks
indicate p < 0.05 as determined by unpaired Student’s t-test analysis (20 Gy vs. daily 2 Gy). (B) The transmigration stimulating factors are of low
molecular weight and sensitive to apyrase treatment. Supernatants of HCC1937 cells irradiated at 20 Gy were collected on day 4 after irradiation
and subjected to ultrafiltration with Vivaspin 2 columns (Molecular weight cut-off 10 kDa) or apyrase treatment (33.3 milliunits active or
heat-inactivated apyrase/ml, 30 min at 37°C). Culture medium supplemented with ATP (200 nM) or SDF-1α (200 ng/ml) was treated in parallel.
Afterwards, transwell migration assays with THP-1 cells were performed and the percentage of transmigrated cells was normalized on the
corresponding untreated control. Means ± s.d. of quadruplicates are shown.
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(yFMI) clearly show that the migratory response of pri-
mary monocytes towards supernatants of ablatively irra-
diated HCC1937 cells was a chemokinetic and not a
chemotactic one (Figure 4A, B). In comparison to the
untreated controls, supernatants of HCC1937 cells irra-
diated at 20 Gy intensified and accelerated monocyte
migration as revealed by significant increases in the ac-
cumulated as well as the euclidean distance. However,
monocyte migration was not directed towards the cham-
ber, in which the supernatant was applied, and the yFMI
value was even negative. Interestingly, parallel results
were obtained for purified ATP supporting the conclu-
sion that in our system nucleotides do not stimulate
chemotaxis but rather chemokinesis as has already been
described by others [44]. For comparison, the chemotac-
tic FPR agonist WKYMVm was employed. Here, the in-
crease in the accumulated distance was comparable to
the one obtained with supernatants of ablatively irradi-
ated HCC1937 cells and ATP, but the acquired euclidean
distance was noticeably higher, and the yFMI was clearly
positive, as the vast majority of cells migrated in the
direction of the gradient. Notably, supernatants of
HCC1937 cells that had been subjected to the fraction-
ated irradiation scheme with daily doses of 2 Gy stimu-
lated monocyte chemokinesis to a lesser, yet in terms of
the accumulated distance still significant extent. Chemo-
kinesis in the presence of supernatants collected from
HCC1937 irradiated at a single dose of 2 Gy did not dif-
fer from the untreated control. Again, apyrase treatment
significantly reduced monocyte chemokinesis stimulated
by supernatants of ablatively irradiated HCC1937 cells,and the median accumulated distance declined to the
level that was observed with supernatants of viable con-
trol cells (Figure 4B, C, D).
Hence, our migration data clearly show that necroti-
cally dying, ablatively irradiated HCC1937 cells - and to
a lesser extent also cells subjected to fractionated irradi-
ation with daily doses of 2 Gy - release low molecular
weight, apyrase-sensitive nucleotides, which stimulate
monocyte chemokinesis in a similar fashion as ATP.
Ablative γ-irradiation induces the upregulation of CD39
surface expression in MCF7 breast cancer cells
In contrast to HCC1937 cells, supernatants of MCF7 cells
did not stimulate monocyte migration, although MCF7
cells strongly underwent primary and secondary necrosis
in response to ablative γ-irradiation with 20 Gy (Figure 2).
Complex nucleotide secretion processes, like the caspase/
pannexin axis, which is activated during apoptosis and has
been described to be impaired in MCF7 cells [46], appar-
ently are of minor importance in case of necrosis-
associated nucleotide release, since during necrosis the
plasma membrane disintegrates and intracellular contents
can passively leak out. Hence, the question that arises is:
why do supernatants of necrotic MCF7 cells not contain
monocyte migration stimulating nucleotides? A conceiv-
able explanation for this observation would be that MCF7
cells express ectonucleotidases, which degrade extracellu-
lar nucleotides [47]. Surface staining of ectonucleotidases
revealed that this in fact was the case (Figure 5A, B and
data not shown). In contrast to HCC1937 and BT474
cells, MCF7 cells showed a low, but well detectable basal
expression of the ectonucleotidase CD39, which was
Figure 4 Apyrase-sensitive nucleotides derived from dying cells stimulate monocyte chemokinesis. (A) Chemotaxis/chemokinesis of
primary human monocytes. HCC1937 cells were treated as in Figure 3A, supernatants were harvested on day 4 after irradiation, and chemotaxis/
chemokinesis of primary human monocytes was analyzed by live cell tracking in IBIDI μ-slide chemotaxis 2D chambers. ATP (1 μM) and the FPR
agonist WKYMVm (1 μg/ml) served as controls. Trajectory paths of 40 randomly picked cells are shown. Black paths depict cells with net migration
upwards, red paths depict cells with net migration downwards. The filled blue circle represents the center of mass after 2 h of migration.
(B) Parameters of chemotaxis/chemokinesis. The trajectory paths of 40 randomly picked cells as shown in (A) were analyzed for accumulated
distance, euclidean distance (linear distance between start and end position), and the forward migration index in y-direction of the gradient
(yFMI =mean of (endpoint in y direction/accumulated distance) of all cells analyzed). Analysis window was set from 10 min to 2 h 10 min (2 h
time frame). Bars indicate the median values of 40 cells analyzed, and p-values were calculated by unpaired Student’s t-test. (C) The chemokinesis
stimulating factors are sensitive to apyrase treatment. Supernatants of HCC1937 cells irradiated at 20 Gy were collected on day 4 after irradiation
and incubated with active or heat-inactivated apyrase (33.3 milliunits apyrase/ml, 50 min at 37°C). Then, they were applied to chemotaxis/
chemokinesis assays with primary human monocytes as in (A). Trajectory paths of 40 randomly picked cells are shown. (D) Accumulated distance
of the plots shown in (C). Bars depict the median values of 40 cells analyzed, and p-values were calculated by unpaired Student’s t-test.
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and to a lesser extent also by fractionated irradiation with
daily doses of 2 Gy (Figure 5A, B). Importantly, pharmaco-
logical inhibition of CD39 ectonucleotidase activity by
addition of ARL-67156 resulted in the release of compar-
able amounts of THP-1 cell migration stimulating factors
by ablatively irradiated MCF7 cells as had been observedwith HCC1937 cells (Figure 5C and Figure 3A). Thus, up-
regulated CD39 apparently degrades extracellular nucleo-
tides released by necrotically dying MCF7 cells.
The irradiation-induced increase in CD39 surface ex-
pression revealed a biphasic kinetics with an initial rise
between days 1 and 2 after irradiation and an even
stronger increase starting on day 3. The basal expression
Figure 5 A blative γ-irradiation induces the upregulation of CD39 surface expression in MCF7 breast cancer cells. (A) CD39 surface
expression on d0 and d4. Breast cancer cells were irradiated as indicated, collected by trypsinization, and CD39 surface expression was analyzed
on d0 and d4 after irradiation by flow cytometry. Representative histograms are shown (black lines represent CD39 staining, filled grey areas the
corresponding isotype controls). (B) Time course of CD39 upregulation. Cells were irradiated as indicated and CD39 surface expression was
analyzed on d0-d4 after irradiation. Relative CD39 surface expression was calculated as the median fluorescence intensities of anti-CD39 staining
subtracted by the corresponding isotype controls. Means ± s.d. of triplicates are shown. (C) Pharmacological inhibition of CD39 ectonucleotidase
results in the release of monocyte migration stimulating factors by ablatively irradiated MCF7 cells. MCF7 cells were irradiated at 20 Gy or left
untreated as in Figure 3A. Then, the CD39 inhibitor ARL-67156 was added at a final concentration of 100 μM and refreshed daily. The collected
culture supernatants were applied to a transwell migration assay with THP-1 cells. Means ± s.d. of quadruplicates are given. (D) In silico analysis of
the human CD39 promoter. Binding sites for nuclear hormone receptors (ER, PR), Egr-1, and others, including Sp-1, Stat-3 and members of the
forkhead transcription factor family (Fox), were identified. (E) Analysis of p21WAF1 and Egr-1 mRNA expression in response to different irradiation
regimes. Cells were irradiated as in (B), and 0–4 days after irradiation p21WAF1 and Egr-1 mRNA levels were determined by qRT-PCR analysis.
Results were normalized on the means of 18S rRNA and β2-microglobulin, and untreated cells (d0) served as calibrator. Means of duplicates
are given.
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others, but the mechanisms, which account for the dif-
ferences in CD39 expression compared to HCC1937 andBT474 cells, are poorly understood [48]. Candidate tran-
scriptional regulators in this regard are p53 and the
nuclear hormone receptors for estrogen (ER) and
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differ in p53 functionality and hormone receptor status
(Figure 1A). In silico analysis of the CD39 promoter re-
gion employing the AliBaba 2.1 platform (http://www.
gene-regulation.com/pub/programs/alibaba2/index.html)
revealed several transcription factor binding sites, in-
cluding sites for the estrogen receptor (ER) and the pro-
gesterone receptor (PR) but no p53 response element
(Figure 5D). Yet, p53- and ER-mediated transcriptional
regulation appear to be closely interconnected, since
they do not only mutually regulate each other’s expres-
sion but also have been described to control target gene
expression in a coordinate manner [49-52]. Hence, p53
and ER might orchestrate basal CD39 expression in
MCF7 cells. Following γ-irradiation, particularly when
applied in an ablative scheme, MCF7 cells showed a ro-
bust activation of p53 as revealed by induction of
p21WAF1 mRNA and protein expression (Figure 5E,
Figure 1D). Hence, activated p53 (in cooperation with
ER) might account for the upregulation of CD39 expres-
sion, since it was only observed in MCF7 cells and the
induction of the prototypical p53 target p21WAF1 dis-
played a comparable biphasic time course as that of
CD39. Nevertheless, indirect mechanisms, including the
p53-mediated activation of other transcriptional regula-
tors, could also be involved. As such Egr-1, an immedi-
ate early response transcription factor, which is well
known to be induced and activated by ionizing irradi-
ation and whose response element was identified close
to the transcription start site within the CD39 promoter
(Figure 5D), was induced in γ-irradiated MCF7 cells in a
similar fashion as p21WAF1 and CD39 [53] (Figure 5E).
Interestingly, Egr-1 has been reported to interact with
p53 and to enhance transcriptional activation by p53
[54,55]. Our data do not allow detailed conclusions on
the mechanisms, which govern irradiation-induced up-
regulation of CD39 expression in MCF7 cells. Neverthe-
less, they support a scenario, in which p53, ER and
Egr-1 could play a crucial role. Further studies are re-
quired to elucidate this issue in greater depth and to find
out if other transcription factors, such as Sp-1, Stat-3 or
NF-kB, also are involved. It should be noted that we also
measured the surface expression levels of CD73 and
CD203c, two other well-known ectonucleotidases, but
we did not detect any basal expression, nor an
irradiation-induced upregulation in the three breast can-
cer cell lines tested (data not shown).
Fast proliferating breast cancer cells with mutant p53 and
a strong necrosis response towards ablative γ-irradiation
release factors that stimulate monocyte migration
In order to examine, whether our findings that fast pro-
liferating, hormone receptor negative HCC1937 breast
cancer cells with defective p53 and a robust necroticresponse towards ablative γ-irradiation release monocyte
migration stimulating nucleotides, are of broader rele-
vance, we analyzed three more cell lines: HCC1806, MDA-
MB468, and BT549 cells. These hormone receptor negative
breast cancer cell lines with mutant p53 (Figure 6A)
exhibited doubling times of 30 h (HCC1806), 51 h (MDA-
MB468) or 77 h (BT549), respectively (Figure 6B). Irradi-
ated HCC1806 and MDA-MB468 cells underwent primary
necrosis to a strong and comparable degree as HCC1937
cells, whereas in slowly proliferating BT549 cells no sig-
nificant induction of necrosis was detected (Figure 6C).
When combining the results of all cell lines analyzed in
the present study, we observed a clear and significant
negative correlation between doubling times and necrosis
induction by ablative irradiation with 20 Gy. This held
true for total as well as primary necrosis in the presence of
zVAD-fmk (Figure 6D). Transwell migration assays with
THP-1 cells revealed that only supernatants of irradiated
HCC1806 and MDA-MB468 but not BT549 cells released
monocyte migration stimulating factors. Again, the stron-
gest monocyte migration was observed with supernatants
of ablatively irradiated cells (Figure 6E). As expected, the
three p53 defective, ER negative cell lines did neither show
any basal CD39 surface expression in FACS analyses, nor
its irradiation-induced upregulation (data not shown). Fi-
nally, we combined the data on THP-1 cell migration and
necrosis induction of all p53 mutant, hormone receptor
negative breast cancer lines. The cell lines with strong ne-
crosis induction in response to γ-irradiation were the
ones, whose supernatants potently stimulated THP-1 cell
migration. Pearson correlation analysis revealed a signifi-
cant positive correlation between the percentage of THP-1
cell migration and the percentage of total necrosis in-
duced. This correlation was even more stringent when
only primary necrosis was considered (Figure 6F).
In summary, our study reveals that fast proliferating,
hormone receptor negative breast cancer cell lines with
defective p53 intensively undergo necrosis in response to
γ-irradiation, particularly when applied in an ablative re-
gime at a single dose of 20 Gy. During necrosis, the cells
release nucleotides, which efficiently stimulate monocyte
migration in a chemokinetic manner. In hormone receptor
positive, p53 wildtype cells, like MCF7, this appears to be
hampered by irradiation-induced upregulation of CD39,
which degrades extracellular nucleotides. Our study opens
several questions, including the detailed molecular mecha-
nisms, which orchestrate irradiation-induced upregulation
of CD39 and the specific role of p53 and the hormone re-
ceptors in this scenario. Moreover, it will be interesting to
further characterize the subpopulation of cells, in which
CD39 expression is increased in response to irradiation.
The biphasic kinetics and the very strong increase 3 days
after irradiation, which parallel senescence induction, sup-
port the hypothesis that it might be the non-necrotic,
Figure 6 Fast proliferating breast cancer cells with mutant p53 and a strong necrosis response towards ablative γ-irradiation release
factors that stimulate monocyte migration. (A) Breast cancer cell lines used. Tumor subtype and receptor status have previously been
reported [29]. p53 mutational status was determined by cDNA sequencing. HCC1806 gave no p53 PCR product, but the mutation in codon 256
was reported before [30]. (B) Growth curve analysis in the presence of 2.5% or 10% FCS. (C) Induction of necrosis in response to irradiation. Cells
were irradiated as indicated ± 50 μM zVAD-fmk. PS externalization and plasma membrane integrity were determined as in Figure 2. Double
positive cells were considered necrotic. Means ± s.d. of triplicates are shown. (D) Fast proliferating cells reveal a stronger necrosis response
towards ablative γ-irradiation. Pearson correlation analysis of doubling times (Figures 1C and 6B) and necrosis (Figures 2A,B and 6C) was performed.
The percentage of total necrotic cells or primary necrotic cells was employed. (E) THP-1 cell migration. Cell-free supernatants were collected 4
days after irradiation and applied to transwell assays as in Figure 3. Means ± s.d. of quadruplicates are given. (F) p53 mutant cell lines with a
strong necrosis response towards ablative γ-irradiation release monocyte migration factors. Pearson correlation analysis of transmigration (Figures
3A and 6E) and necrosis (Figures 2A,B and 6C) 4 days after irradiation (0 Gy, 2 Gy, daily 2 Gy, or 20 Gy) was performed for p53 mutant cells. The
percentage of total or primary necrotic cells was used as in (D). (G) Conclusions. Ablative γ-irradiation induces a strong necrotic response in fast
proliferating breast cancer cell lines. The concomitant release of nucleotides stimulates monocyte migration and chemokinesis. In p53 wildtype,
hormone receptor positive MCF7 cells this is impaired due to irradiation-induced upregulation of CD39, which degrades extracellular nucleotides.
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relevance of our findings has to be explored. Future stud-
ies have to address the question, whether ablative irradi-
ation can stimulate monocyte migration and intra-tumoral
monocyte recruitment in vivo. In this regard it will be of
special importance to elucidate if the chemokinetic mono-
cyte response that we have observed in vitro might be
translated into a directional recruitment into the tumor.
Intriguingly, different models of sterile injury have re-
vealed that endothelial cells and pericytes can convert thedanger signals released by necrotically dying cells into cas-
cades of chemokine gradients and adhesion molecules,
which govern the recruitment of monocytes and neutro-
phils to the site of injury [56,57]. Along the same line, it
has been shown for systemic anthracycline therapy that
nucleotides released from dying cancer cells stimulate the
intra-tumoral recruitment of a CD11c+CD11b+Ly6Chi
monocytic cell type, which can differentiate into highly
potent APCs, engulf tumor material, present it to T cells,
and thereby initiate a productive anti-tumor immune
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http://www.ro-journal.com/content/9/1/85response [20]. Extracellular nucleotides appear to be of
crucial importance in this context, since they do not only
contribute to monocyte recruitment, but also support
monocyte activation and differentiation as well as their
intra-tumoral survival [20,58]. Hence, it is tempting to
speculate that local ablative radiotherapy might be utilized
for fast proliferating, hormone receptor negative, p53 mu-
tant breast cancer in order to induce anti-tumor immune
responses.
Conclusions
Here, we show that fast proliferating, hormone receptor
negative breast cancer cell lines with mutant p53 inten-
sively undergo necrosis in response to γ-irradiation, es-
pecially when applied in an ablative setting at a single
dose of 20 Gy. These necrotically dying cancer cells re-
lease nucleotides, which stimulate monocyte migration
and chemokinesis. In contrast, hormone receptor posi-
tive cells with wildtype p53 upregulate CD39 ectonu-
cleotidase expression in response to irradiation, and thus
do not stimulate monocyte migration. Future studies
have to clarify, whether ablative radiotherapy might be
utilized for local necrosis induction and concomitant nu-
cleotide release by the dying cancer cells in order to
achieve intra-tumoral monocyte recruitment, APC dif-
ferentiation, and subsequent priming of adaptive anti-
tumor immune responses - not only in the context of
fast proliferating, hormone receptor negative and p53
mutant breast cancer.
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